TimesSquare Capital Management LLC reduced its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,509 shares of the company’s stock after selling 19,021 shares during the period. argenex comprises about 1.4% of TimesSquare Capital Management LLC’s holdings, making the stock its 16th largest holding. TimesSquare Capital Management LLC owned approximately 0.18% of argenex worth $91,251,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ARGX. AQR Capital Management LLC raised its stake in shares of argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares in the last quarter. Focus Partners Wealth raised its stake in shares of argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of argenex by 60.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on ARGX shares. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. HC Wainwright raised their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Citizens Jmp raised their price target on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday, February 27th. Finally, Guggenheim raised their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,017.78.
argenex Stock Performance
Shares of NASDAQ ARGX opened at $776.26 on Tuesday. The firm has a market cap of $48.03 billion, a price-to-earnings ratio of 34.56, a P/E/G ratio of 1.28 and a beta of 0.46. The business’s 50-day simple moving average is $761.26 and its 200-day simple moving average is $816.23. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.
argenex (NASDAQ:ARGX – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. As a group, equities research analysts forecast that argenex SE will post 25.08 earnings per share for the current year.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Further Reading
- Five stocks we like better than argenex
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
